Abstract：
We present the case of a 35-y-old woman with short bowel syndrome secondary to extensive intestinal resection with associated chronic kidney disease who was undergoing hemodialysis. This patient required permanent supplementation with intradialytic parenteral nutrition because of a high-output end-jejunostomy. The patient was a candidate for treatment with teduglutide, a glucagon-like peptide 2 analog, intending to increase intestinal absorption. A complete nutritional assessment was performed using bioelectrical impedance vector analysis. Teduglutide treatment was successful, and after a 1-y follow-up, the patient had considerably reduced end-jejunostomy output (reduction of 6 L/d) and an improved nutritional status (9.1 kg weight gain, 1.4 kg fat-free mass gain, and a 2.2-degree increase in bioimpedance phase angle). However, we have been unable to reduce intradialytic parenteral nutrition, which the patient requires thrice weekly. No significant secondary effects have occurred because of teduglutide administration. This may be the first reported use of teduglutide in a patient with short bowel syndrome undergoing hemodialysis who was monitored using bioelectrical impedance data during follow-up.
摘要：
我们介绍了一名35岁的女性，患有广泛的肠切除术继发的短肠综合征，并伴有相关的慢性肾脏疾病，正在接受血液透析。由于高产量的空肠端造口术，该患者需要永久性补充透析中的肠外营养。该患者是teduglutide治疗的候选人，胰高血糖素样肽2类似物，旨在增加肠道吸收。使用生物电阻抗矢量分析进行完整的营养评估。Teduglutide治疗成功,经过1年的随访，患者的空肠末端造口输出显著减少（减少6L/d），营养状况改善（体重增加9.1kg，1.4kg无脂增重，和生物阻抗相位角增加2.2度）。然而,我们一直无法减少透析中的肠外营养，病人每周需要三次。由于使用teduglutide，没有发生明显的副作用。这可能是首次报道在接受血液透析的短肠综合征患者中使用teduglutide，该患者在随访期间使用生物电阻抗数据进行监测。
